Literature DB >> 27253484

Update on biphasic anaphylaxis.

Sangil Lee1, Annie T Sadosty, Ronna L Campbell.   

Abstract

PURPOSE OF REVIEW: Biphasic anaphylaxis is a well documented complication of anaphylaxis, but it has been inconsistently defined in the literature. Analysis of contemporary studies of biphasic anaphylaxis based on modern definitions is needed. RECENT
FINDINGS: The rate of biphasic reactions in contemporary literature ranges from 0.4 to 14.7% depending on the study population. Observational studies have reported risk factors associated with the development of biphasic reactions; however, findings have been inconsistent and of questionable generalizability. Although life-threatening biphasic reactions are rare, up to 50% of biphasic reactions will require treatment with epinephrine. Early epinephrine administration may have a role in prevention of biphasic reactions, but the role of steroids needs further investigation. The optimal duration of observation is yet to be determined.
SUMMARY: Given the relative rarity of life-threatening biphasic anaphylaxis and the new context of the NIAID/FAAN standardized definition, further research regarding biphasic anaphylaxis is needed to better elucidate the care model for anaphylaxis patients with a focus on: prevention of biphasic reactions; identification of patients at increased risk of a biphasic reaction; determination of appropriate observation strategies for anaphylaxis patients; and patient education and preparation for management of potential biphasic reactions.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27253484     DOI: 10.1097/ACI.0000000000000279

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  10 in total

Review 1.  Anaphylaxis.

Authors:  Daniel LoVerde; Onyinye I Iweala; Ariana Eginli; Guha Krishnaswamy
Journal:  Chest       Date:  2017-08-08       Impact factor: 9.410

2.  Persistent, refractory, and biphasic anaphylaxis: A multidisciplinary Delphi study.

Authors:  Timothy E Dribin; Hugh A Sampson; Carlos A Camargo; David C Brousseau; Jonathan M Spergel; Mark I Neuman; Marcus Shaker; Ronna L Campbell; Kenneth A Michelson; Susan A Rudders; Amal H Assa'ad; Kimberly A Risma; Mariana Castells; Lynda C Schneider; Julie Wang; Juhee Lee; Rakesh D Mistry; David Vyles; Lisa M Vaughn; Daniel J Schumacher; John K Witry; Shiv Viswanathan; Erica M Page; David Schnadower
Journal:  J Allergy Clin Immunol       Date:  2020-08-24       Impact factor: 10.793

Review 3.  The pathophysiology of anaphylaxis.

Authors:  Laurent L Reber; Joseph D Hernandez; Stephen J Galli
Journal:  J Allergy Clin Immunol       Date:  2017-08       Impact factor: 10.793

4.  Risk Factors for Severe Reactions during Double-Blind Placebo-Controlled Food Challenges.

Authors:  Noriyuki Yanagida; Sakura Sato; Tomoyuki Asaumi; Kiyotake Ogura; Motohiro Ebisawa
Journal:  Int Arch Allergy Immunol       Date:  2017-04-06       Impact factor: 2.749

Review 5.  Overview of Allergy and Anaphylaxis.

Authors:  Timothy E Dribin; Megan S Motosue; Ronna L Campbell
Journal:  Emerg Med Clin North Am       Date:  2021-10-29       Impact factor: 2.264

Review 6.  Anaphylaxis.

Authors:  David Fischer; Timothy K Vander Leek; Anne K Ellis; Harold Kim
Journal:  Allergy Asthma Clin Immunol       Date:  2018-09-12       Impact factor: 3.406

7.  Identification of children with anaphylaxis at low risk of receiving acute inpatient therapies.

Authors:  Timothy E Dribin; Kenneth A Michelson; Michael C Monuteaux; Anne M Stack; Karen S Farbman; Lynda C Schneider; Mark I Neuman
Journal:  PLoS One       Date:  2019-02-07       Impact factor: 3.240

8.  Simulation of Health and Economic Benefits of Extended Observation of Resolved Anaphylaxis.

Authors:  Marcus Shaker; Dana Wallace; David B K Golden; John Oppenheimer; Matthew Greenhawt
Journal:  JAMA Netw Open       Date:  2019-10-02

9.  PEMCRC anaphylaxis study protocol: a multicentre cohort study to derive and validate clinical decision models for the emergency department management of children with anaphylaxis.

Authors:  Timothy E Dribin; Kenneth A Michelson; David Vyles; Mark I Neuman; David C Brousseau; Rakesh D Mistry; Peter S Dayan; Nanhua Zhang; Shiv Viswanathan; John Witry; Stephanie Boyd; David Schnadower
Journal:  BMJ Open       Date:  2021-01-05       Impact factor: 2.692

10.  Biphasic anaphylaxis after first dose of mRNA COVID-19 vaccine with positive polysorbate 80 skin testing.

Authors:  Mitchell M Pitlick; Miguel A Park; Alexei Gonzalez-Estrada; Sergio E Chiarella
Journal:  Ann Allergy Asthma Immunol       Date:  2021-07-31       Impact factor: 6.347

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.